NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Tiziana Life Sciences Ltd. TLSA
9 fiscal years on record · USD · FY2024 reported · SEC filings only
$-11.9M
$-1.5M
Growth
—
Revenue, FY2024 · full 9-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
Not available in our data for this period.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · |
| Income tax $B | −0.0 | 0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | · | · | −0.0 | −0.0 | −0.0 | · | −0.0 | · |
| EPS, diluted $ | −0.11 | −0.17 | −0.15 | −0.24 | −0.16 | · | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 3 failures in 34 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 42 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code D0
Fiscal year endsDecember 31
Data on record since2016